ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $115,170 | -7.9% | 18,516 | 0.0% | 0.00% | – |
| Q3 2022 | $125,000 | +5.9% | 18,516 | -1.1% | 0.00% | – |
| Q2 2022 | $118,000 | +14.6% | 18,726 | -14.6% | 0.00% | – |
| Q1 2022 | $103,000 | -59.8% | 21,916 | +140.2% | 0.00% | – |
| Q1 2021 | $256,000 | -26.9% | 9,124 | -31.2% | 0.00% | – |
| Q4 2020 | $350,000 | -0.6% | 13,268 | +41.5% | 0.00% | -100.0% |
| Q3 2020 | $352,000 | -96.7% | 9,374 | -95.5% | 0.00% | -95.2% |
| Q2 2020 | $10,806,000 | +67.3% | 210,610 | +3.9% | 0.02% | +40.0% |
| Q1 2020 | $6,460,000 | -44.2% | 202,631 | +5.1% | 0.02% | -25.0% |
| Q4 2019 | $11,570,000 | +951.8% | 192,711 | +542.4% | 0.02% | +900.0% |
| Q3 2019 | $1,100,000 | -56.8% | 30,000 | -45.2% | 0.00% | -60.0% |
| Q2 2019 | $2,545,000 | -48.6% | 54,702 | -55.6% | 0.01% | -44.4% |
| Q1 2019 | $4,952,000 | -55.3% | 123,334 | -48.7% | 0.01% | -55.0% |
| Q4 2018 | $11,067,000 | – | 240,590 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |